Filing Flows › Opus Genetics (IRD) › Q1 2026
Opus Genetics (IRD) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Opus Genetics (IRD) reported revenue of $2.2M for the first quarter 2026 (Q1 2026), -51% from a year earlier and -44% from the quarter before. Operating margin was -665.9%.
Opus Genetics, Q1 2026: revenue $2.2M (-51% year over year), operating margin -665.9%, net loss $65.5M, operating cash flow −$12.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | -44% | -51% |
| Operating profit | −$14.4M | — | — |
| Net earnings | −$65.5M | — | — |
| Operating cash flow | −$12.7M | — | — |
What changed
Revenue was $2.2M in Q1 2026, down 51% year over year and down 44% from the previous quarter.
Operating costs exceeded revenue by $14.4M, an operating margin of -665.9%. Total costs grew 16% against a revenue fall of 51%. The fastest-growing cost line was Research & development (+33%). The quarter ended with a net loss of $65.5M, wider than the previous quarter's $16.5M loss. Net interest and other expense of $51.2M was the main reason.
Operating cash flow was −$12.7M. Non-cash charges added back $13K of depreciation and $1.5M of share-based compensation. Working capital and other items added $51.3M.
Questions
What was Opus Genetics' revenue in the first quarter 2026?
Opus Genetics (IRD) reported revenue of $2.2M for the first quarter 2026 (Q1 2026), -51% from a year earlier and -44% from the quarter before.
Was Opus Genetics profitable in the first quarter 2026?
Operating loss was $14.4M (-665.9% of revenue) and net loss $65.5M.
Source: Opus Genetics 10-Q on SEC EDGAR.